Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 1, Open-Label, Multicenter, Multidose, Dose Escalation Study of BMS-936558 (Nivolumab) in Subjects With Selected Advanced or Recurrent Malignancies
Brief Summary: The purpose of this study is to determine the safety and effectiveness of MDX-1106 in patients with certain types of cancer. Another purpose is to determine how MDX-1106 is absorbed and distributed within the body, and how it's eventually eliminated.


Options:
A: Arm Label: Tecemotide (L-BLP25); Type: EXPERIMENTAL; Interventions: Biological: Tecemotide (L-BLP25), Drug: Single low dose cyclophosphamide | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: BIOLOGICAL; Name: Tecemotide (L-BLP25); Assigned to Arm(s): Tecemotide (L-BLP25) | Intervention Type: DRUG; Name: Single low dose cyclophosphamide; Assigned to Arm(s): Tecemotide (L-BLP25) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Investigational Arm; Type: EXPERIMENTAL; Interventions: Biological: Tecemotide, Drug: Single low dose cyclophosphamide, Other: Best Supportive Care (BSC) | Arm Label: Control Arm; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Other: Saline, Other: Best Supportive Care (BSC) | Intervention Type: BIOLOGICAL; Name: Tecemotide; Assigned to Arm(s): Investigational Arm | Intervention Type: DRUG; Name: Single low dose cyclophosphamide; Assigned to Arm(s): Investigational Arm | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Control Arm | Intervention Type: OTHER; Name: Saline; Assigned to Arm(s): Control Arm | Intervention Type: OTHER; Name: Best Supportive Care (BSC); Assigned to Arm(s): Control Arm, Investigational Arm
C: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: PF-3512676 + Erlotinib | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Erlotinib | Intervention Type: DRUG; Name: PF-3512676 + Erlotinib; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Erlotinib; Assigned to Arm(s): B
D: Arm Label: Melanoma - BMS-936558 (MDX-1106); Type: EXPERIMENTAL; Interventions: Biological: BMS-936558 (MDX-1106) | Arm Label: RCC - BMS-936558 (MDX-1106); Type: EXPERIMENTAL; Interventions: Biological: BMS-936558 (MDX-1106) | Arm Label: mCRPC - BMS-936558 (MDX-1106); Type: EXPERIMENTAL; Interventions: Biological: BMS-936558 (MDX-1106) | Arm Label: NSCLC - BMS-936558 (MDX-1106); Type: EXPERIMENTAL; Interventions: Biological: BMS-936558 (MDX-1106) | Arm Label: CRC - BMS-936558 (MDX-1106); Type: EXPERIMENTAL; Interventions: Biological: BMS-936558 (MDX-1106) | Intervention Type: BIOLOGICAL; Name: BMS-936558 (MDX-1106); Assigned to Arm(s): Melanoma - BMS-936558 (MDX-1106) | Intervention Type: BIOLOGICAL; Name: BMS-936558 (MDX-1106); Assigned to Arm(s): RCC - BMS-936558 (MDX-1106) | Intervention Type: BIOLOGICAL; Name: BMS-936558 (MDX-1106); Assigned to Arm(s): mCRPC - BMS-936558 (MDX-1106) | Intervention Type: BIOLOGICAL; Name: BMS-936558 (MDX-1106); Assigned to Arm(s): NSCLC - BMS-936558 (MDX-1106) | Intervention Type: BIOLOGICAL; Name: BMS-936558 (MDX-1106); Assigned to Arm(s): CRC - BMS-936558 (MDX-1106)

Answer: D